SMT201900436T1 - Derivati c17-alcandiilici e alchendiilici dell'acido oleoanolico e metodi del loro uso - Google Patents

Derivati c17-alcandiilici e alchendiilici dell'acido oleoanolico e metodi del loro uso

Info

Publication number
SMT201900436T1
SMT201900436T1 SM20190436T SMT201900436T SMT201900436T1 SM T201900436 T1 SMT201900436 T1 SM T201900436T1 SM 20190436 T SM20190436 T SM 20190436T SM T201900436 T SMT201900436 T SM T201900436T SM T201900436 T1 SMT201900436 T1 SM T201900436T1
Authority
SM
San Marino
Prior art keywords
alkanediyl
methods
oleanolic acid
alkenediyl
derivatives
Prior art date
Application number
SM20190436T
Other languages
English (en)
Italian (it)
Inventor
Eric Anderson
Xin Jiang
Christopher F Bender
Melean Visnick
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49253402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201900436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of SMT201900436T1 publication Critical patent/SMT201900436T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SM20190436T 2012-09-10 2013-09-10 Derivati c17-alcandiilici e alchendiilici dell'acido oleoanolico e metodi del loro uso SMT201900436T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261699122P 2012-09-10 2012-09-10
US201361780540P 2013-03-13 2013-03-13
PCT/US2013/059027 WO2014040060A1 (en) 2012-09-10 2013-09-10 C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
EP13767176.4A EP2892912B1 (en) 2012-09-10 2013-09-10 C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof

Publications (1)

Publication Number Publication Date
SMT201900436T1 true SMT201900436T1 (it) 2019-09-09

Family

ID=49253402

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190436T SMT201900436T1 (it) 2012-09-10 2013-09-10 Derivati c17-alcandiilici e alchendiilici dell'acido oleoanolico e metodi del loro uso

Country Status (38)

Country Link
US (2) US9593074B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2892912B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6243428B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102237359B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104955833B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR092506A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013312106B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015005168A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2882418C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015000543A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20150117A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1121776T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2892912T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2015000054A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA029174B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2731758T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20191165T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE044126T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL237639B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN01442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2892912T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME03522B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX366913B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY180903A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ630967A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20150627A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015500491A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2892912T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2892912T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS59194B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201501792RA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2892912T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201900436T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI630212B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA115672C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY35023A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014040060A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201501206B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
EP2279196B1 (en) 2008-04-18 2015-01-21 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
EP2651902B1 (en) 2010-12-17 2017-11-08 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
WO2013139766A1 (en) * 2012-03-20 2013-09-26 Firmenich Sa Compounds for a controlled release of active perfuming molecules
MX387999B (es) 2012-04-27 2025-03-19 Reata Pharmaceuticals Holdings Llc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos.
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
ES2865163T3 (es) 2015-09-23 2021-10-15 Reata Pharmaceuticals Inc Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos
EP3538104A1 (en) 2016-11-08 2019-09-18 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
AU2018334386B2 (en) 2017-09-14 2021-11-04 Phoenix Biotechnology, Inc. Method and composition for treating viral infection
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
US9896476B1 (en) 2017-09-21 2018-02-20 King Saud University Glycyrrhetic acid derivatives
CA3103726A1 (en) 2018-06-15 2019-12-19 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CN108640965B (zh) * 2018-06-23 2021-11-05 沈阳药科大学 2-取代-18β-甘草次酸衍生物及其应用
JP7695229B2 (ja) 2019-07-19 2025-06-18 リアタ ファーマシューティカルズ インコーポレイテッド Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
WO2022155614A1 (en) * 2021-01-18 2022-07-21 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6365768B1 (en) 1999-05-14 2002-04-02 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) * 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
WO2002026762A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002047611A2 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
WO2003059339A1 (en) 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2003062260A1 (en) 2002-01-18 2003-07-31 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
CA2485565A1 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
WO2008000070A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
CN101117348B (zh) 2006-08-01 2010-12-29 浙江海正药业股份有限公司 A环和c环多氧化取代的五环三萜及其制备方法和用途
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) * 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
EP2279196B1 (en) 2008-04-18 2015-01-21 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
AU2009237581C1 (en) * 2008-04-18 2014-12-04 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
BRPI0911208B1 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals, Inc Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
SI2558105T1 (sl) 2010-04-12 2020-02-28 Reata Pharmaceuticals, Inc. Bardoksolon metil za zdravljenje debelosti
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
EP2651902B1 (en) 2010-12-17 2017-11-08 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
PH12013501528A1 (en) 2011-01-31 2013-09-16 Bristol Myers Squibb Co C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
CN102093462B (zh) 2011-02-28 2012-11-21 贵州省中国科学院天然产物化学重点实验室 1α,2α-二羟基齐墩果酸的制备方法和应用
ES2729405T3 (es) * 2011-03-11 2019-11-04 Reata Pharmaceuticals Inc Derivados triterpenoides de C4-monometilo y métodos de uso de los mismos
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN102250189B (zh) 2011-05-20 2012-08-29 中国药科大学 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
MX387999B (es) 2012-04-27 2025-03-19 Reata Pharmaceuticals Holdings Llc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos.
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8980898B2 (en) 2012-05-29 2015-03-17 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CN104603125A (zh) 2012-09-10 2015-05-06 弗·哈夫曼-拉罗切有限公司 用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
US20140073700A1 (en) 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
DK2892911T3 (en) 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
EP2739639A4 (en) 2012-09-28 2014-11-05 Applied Pharmaceutical Science Inc POLYMORPHES OF CDDO ETHYL SITES AND USES THEREOF
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN103788166A (zh) 2012-10-30 2014-05-14 中国药科大学 △13（18）-cddo衍生物、其制备方法与在制药中的用途
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
MX380589B (es) 2013-08-23 2025-03-12 Reata Pharmaceuticals Holdings Llc Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxolona o sus análogos.
ES2865163T3 (es) 2015-09-23 2021-10-15 Reata Pharmaceuticals Inc Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos

Also Published As

Publication number Publication date
PL2892912T3 (pl) 2019-10-31
AU2013312106B2 (en) 2018-03-08
AU2013312106A1 (en) 2015-03-12
NZ630967A (en) 2016-10-28
JP2015529228A (ja) 2015-10-05
IL237639B (en) 2020-04-30
CY1121776T1 (el) 2020-07-31
CL2015000543A1 (es) 2015-12-04
US10501489B2 (en) 2019-12-10
CN104955833A (zh) 2015-09-30
CR20150117A (es) 2016-10-10
US20170260227A1 (en) 2017-09-14
HK1212355A1 (en) 2016-06-10
EA029174B1 (ru) 2018-02-28
SI2892912T1 (sl) 2019-07-31
RS59194B1 (sr) 2019-10-31
ES2731758T3 (es) 2019-11-18
DK2892912T3 (da) 2019-06-24
PE20150627A1 (es) 2015-06-04
EP2892912A1 (en) 2015-07-15
MY180903A (en) 2020-12-11
MX2015003079A (es) 2015-07-14
KR20150054961A (ko) 2015-05-20
UY35023A (es) 2014-03-31
SG11201501792RA (en) 2015-05-28
WO2014040060A1 (en) 2014-03-13
JP6243428B2 (ja) 2017-12-06
CA2882418C (en) 2021-05-04
EA201590540A1 (ru) 2015-08-31
CN104955833B (zh) 2019-10-11
ME03522B (me) 2020-04-20
BR112015005168A2 (pt) 2017-08-15
TW201410698A (zh) 2014-03-16
US20140100227A1 (en) 2014-04-10
HUE044126T2 (hu) 2019-09-30
EP2892912B1 (en) 2019-04-24
PH12015500491B1 (en) 2015-04-27
MX366913B (es) 2019-07-30
AR092506A1 (es) 2015-04-22
IN2015DN01442A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-03
PT2892912T (pt) 2019-07-12
TWI630212B (zh) 2018-07-21
KR102237359B1 (ko) 2021-04-06
HRP20191165T1 (hr) 2019-10-04
CA2882418A1 (en) 2014-03-13
UA115672C2 (uk) 2017-12-11
DOP2015000054A (es) 2015-05-31
US9593074B2 (en) 2017-03-14
ZA201501206B (en) 2017-08-30
IL237639A0 (en) 2015-04-30
PH12015500491A1 (en) 2015-04-27
LT2892912T (lt) 2019-07-10

Similar Documents

Publication Publication Date Title
IL237639B (en) Alkanedial and alkanedial derivatives at the 17th carbon position of oleinolic acid and methods of using them
IL237638A0 (en) Heteroaryl c17 derivatives of olanolic acid and methods of using them
LT2683731T (lt) C4-monometiltriterpenoido dariniai ir jų panaudojimo būdai
SG10201609940RA (en) Compounds and their methods of use
IL238662A0 (en) Bendamustine derivatives and methods of using them
IL237421A0 (en) Compositions for body surfaces and their use
IL236965B (en) Derivatives of 5-aminolevulinic acid and uses thereof
ZA201503171B (en) Modified hyaluronic acid derivatives and use thereof
EP2986112A4 (en) PREPARATION AND USE OF FULVINIC ACID DERIVATIVES
IL238934A0 (en) Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use